ArticleRadiation oncology (London, England)2026
Comparative study between PET-CT simulation and CT for head and neck cancer treatment and their potential effect on the thyroid gland: a prospective comparative study.
Article in Radiation oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadiotherapy (RT) plays a key role in multidisciplinary treatment of Head and neck cancers (HNCs). Over the past two decades, advances have improved RT's tumor control and toxicity profiles. Precise delineation of gross tumor volume and organs at risk using CT and PET-CT is crucial for safe and effective RT. Additionally, RT increases the risk of thyroid dysfunction, especially hypothyroidism.
aimThe present study compared PET-CT simulation and CT-alone planning in head and neck cancer (HNC) treatment, emphasizing their effects on thyroid gland function.
methodsThe patients were divided into two groups according to the simulation method (PET-CT or CT), two fresh blood samples (5 mL/ sample) were collected from each patient, before and after radiotherapy. TSH, FT3, and FT4 (Thyroid biomarkers) were assessed by electrochemiluminescent immunoassay (ECLIA).
resultsPET-CT simulation demonstrated a significant improvement in GTVp delineation accuracy by 71.8% compared with CT. After radiotherapy, TSH levels show minor decline changes, whereas FT3 and FT4 levels declined significantly, with greater declines observed in stages II and III. The most common tumor site was the larynx (60% in PET-CT, 75% in CT), followed by the tongue, nasopharynx, and parotid gland.
conclusionPET-CT simulation offered superior GTVp delineation accuracy over CT, improving HNCs radiotherapy planning. Immediately after RT, radiotherapy caused significant declines in serum FT3 and FT4 levels, with only a minor, non-significant TSH declining, particularly in stage II/III disease. Notably FT4 is little more affected in PET-CT simulation patient group, highlighting the need for thyroid function monitoring. These results advocate PET-CT integration in planning and routine endocrine monitoring for treatment complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.